The Role of IL-6 Signaling in Cancer-induced Bone Pain

Cancer pain is the most frequent, feared, and disruptive symptom of the disease and is a primary factor in diminished quality of life in cancer patients. Moreover, opiates, commonly used for moderate-to-severe cancer pain, are associated with debilitating side effect that further diminish the patients' quality of life. There is a need for testing and development of improved therapies for cancer-induced pain. The proposed experiments examine whether prolonged blockage of IL-6 signaling will effectively block tumor-induced cancer pain, and if alleviation of cancer-induced pain will correspond to altered disease progression.

You can learn more about cancer pain research in our Q&A interview with Dr. King...

Organization: 
University of New England
Researcher: 
Tamara King
Grant Amount Given: 
$139,633
Year Issued: 
2012
Period: 
Spring
Grant Category: 
Research
Types of Cancer: 
Bone
Grant Duration: 
2 Year Accelerator Grant

Maine Cancer Foundation Grants to this Organization:

Year Program Amount Category Organization
2013 Improving the Treament of Cancer Related Pain $22,540 Education University of New England
2013 The Role of the Kappa Opioid Receptor in Regulating Cancer Proliferation in Vitro and In Vivo $50,000 Research University of New England
2012 Feasibility of Using SEER-Medicare Data to Assess the Influence of ESA Policy Changes on Outcomes $55,936 Research University of New England
2012 The Role of IL-6 Signaling in Cancer-induced Bone Pain $139,633 Research University of New England
2011 Non-Psychotropic Cannabinoid2 Receptor Agonists Inhibit Breast Cancer Proliferation $105,197 Research University of New England
2008 Role of Delta Opioid Receptors in Bone Cancer $81,995 Research University of New England
2002 Occupational Therapy Education $5,000 Education University of New England
2001 The Impact of Chemotherapy on Memory in Women with Breast Cancer $5,074 Research University of New England